AngioDynamics Bundle
Who Really Controls AngioDynamics?
Understanding a company's ownership is crucial for investors and stakeholders alike. The structure of ownership dictates strategic decisions and ultimately influences a company's success. This analysis dives deep into the AngioDynamics SWOT Analysis to uncover the key players shaping the future of this medical technology innovator.
This exploration of AngioDynamics ownership will reveal the identities of its major shareholders and the evolution of its ownership structure. We'll examine the influence of key AngioDynamics investors and the composition of the AngioDynamics board of directors. Understanding the dynamics of AngioDynamics stock ownership is key to grasping the company's trajectory and potential for future growth, providing valuable insights for anyone interested in the AngioDynamics company profile.
Who Founded AngioDynamics?
The story of AngioDynamics begins in 1988, stemming from E-Z-EM, a company co-founded by Howard S. Stern. This marked the initial phase of what would become a significant player in the medical technology field. Eamonn P. Hobbs, with his expertise in interventional radiology, played a crucial role in establishing AngioDynamics.
From its inception, AngioDynamics focused on research and development, specifically targeting the medical plastics market for interventional radiology. Early products like the Schon Acute Hemodialysis Catheter and the Uni-Fuse Infusion Catheter were among the first steps in its product portfolio. Howard S. Stern's guidance was crucial, serving as a director and later as chairman of the board, guiding the company's evolution.
While specific details on the initial equity distribution among the founders are not readily available in public records, it's understood that E-Z-EM held a substantial stake. This setup laid the groundwork for AngioDynamics to eventually become a publicly traded company, marking a significant transition in its ownership structure.
Early Leadership
Howard S. Stern, a co-founder, served as a director and chairman, providing crucial leadership. Eamonn P. Hobbs, with expertise in interventional radiology, was instrumental in the company's establishment.
Initial Focus
The company's early focus was on research and development of medical plastics products. These products were designed for the emerging field of interventional radiology.
Ownership Structure
Initially, AngioDynamics was a division of E-Z-EM, suggesting E-Z-EM held a significant stake. This structure evolved as AngioDynamics grew and eventually became a publicly traded company.
Product Development
Early products included the Schon Acute Hemodialysis Catheter and the Uni-Fuse Infusion Catheter. These products were designed to meet the needs of interventional radiology.
Transition to Public
AngioDynamics transitioned from a division of E-Z-EM to a publicly traded entity. This transition marked a significant shift in its ownership and capital structure.
Founding Details
The company was founded in 1988 as a division of E-Z-EM. Eamonn P. Hobbs and Howard S. Stern were key figures in the company's establishment.
Understanding the early ownership of AngioDynamics provides a foundation for analyzing its current Growth Strategy of AngioDynamics. The company's history, from its roots within E-Z-EM to its current status as a publicly traded entity, is essential for investors seeking to understand the evolution of AngioDynamics ownership and its impact on the company’s performance. Information about the company's early shareholders is not readily available, but understanding the transition from a division of E-Z-EM to an independent entity is key to grasping the company’s financial journey.
AngioDynamics SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has AngioDynamics’s Ownership Changed Over Time?
The evolution of AngioDynamics' ownership structure is marked by its initial public offering (IPO) in May 2004. This transition from a private to a public entity significantly broadened its shareholder base. The IPO, priced at $11.00 per share, offered 1,950,000 shares, providing access to capital markets and setting the stage for future ownership dynamics.
As a publicly traded company, AngioDynamics' ownership has shifted over time, with institutional investors playing a dominant role. The company's stock symbol is ANGO. The company's history includes strategic acquisitions and product innovations, influencing investor interest and shareholding patterns. Understanding the company's structure is key for those looking to learn how to buy AngioDynamics stock.
| Shareholder Type | Percentage of Ownership (May 2025) | Shares Held (March 31, 2025) |
|---|---|---|
| Institutional Investors | 94.31% | Varies |
| Insider Holdings | 4.32% | Varies |
| Mutual Funds | 43.14% | Varies |
The major shareholders of AngioDynamics as of March 31, 2025, include BlackRock, Inc. (8.507%), Systematic Financial Management LP (6.171%), and The Vanguard Group Inc. (6.16%). These institutional investors, along with others like Armistice Capital, LLC, Segall Bryant & Hamill, LLC, and Nuveen Asset Management, LLC, collectively hold a significant portion of the company's shares. The company's financial performance, including its 2024 revenue of $303.91 million and a reported loss of -$184.35 million, also influences investor sentiment and shareholding decisions. For more details, you can read about the company's information.
Key Takeaways on AngioDynamics Ownership
AngioDynamics' ownership structure is primarily dominated by institutional investors, reflecting its status as a publicly traded medical device company. Understanding the major shareholders, including BlackRock and The Vanguard Group, provides insights into investor confidence and market dynamics.
- Institutional investors hold the majority of shares.
- Insider holdings remain a consistent percentage.
- Mutual funds have increased their stake.
- Revenue in 2024 was $303.91 million.
AngioDynamics PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on AngioDynamics’s Board?
The current board of directors of the company, as of May 2025, includes Howard Donnelly as Chairman and Jim Clemmer as President and CEO. Other board members include Eileen Auen, Lorinda Burgess, and Wesley Johnson. Understanding the composition of the board is crucial for AngioDynamics' company profile, as it directly influences strategic decisions and corporate governance. Jim Clemmer, who has served as CEO since April 2016, also holds a direct ownership stake of 1.17% of the company's shares, which is valued at approximately $5.20 million.
The board's structure and leadership have seen recent changes. In February 2024, Wesley Johnson was appointed as the new chair of the Audit Committee, and Jan Stern Reed became the new chair of the Nominating, Compliance, and Corporate Governance Committee. These changes reflect the ongoing evolution of the company's governance practices and the board's commitment to effective oversight. The board's composition and the roles of its members are key factors for AngioDynamics investors to consider when evaluating the company's performance and future prospects.
| Board Member | Position | Ownership |
|---|---|---|
| Howard Donnelly | Chairman | N/A |
| Jim Clemmer | President and CEO | 1.17% |
| Eileen Auen | Director | N/A |
| Lorinda Burgess | Director | N/A |
| Wesley Johnson | Director | N/A |
The voting structure for shareholders is based on a plurality vote for the election of directors. This means that the candidates who receive the most votes are elected. The company's Amended and Restated Certificate of Incorporation and By-Laws, along with Delaware law, govern these voting requirements. In the November 2024 Annual Meeting of Shareholders, nominees for Class III directors, including Lorinda A. Burgess and Wesley E. Johnson, Jr., were elected to serve until the 2027 Annual Meeting. This structure ensures that AngioDynamics shareholders have a voice in the company's direction, influencing the overall AngioDynamics ownership and governance.
Voting Power and Shareholder Influence
Shareholders of the company vote on important matters. These include the election of directors, ratification of independent registered public accounting firms, and advisory votes on executive compensation. The voting structure is based on a plurality vote for electing directors.
- Voting on director elections.
- Ratification of accounting firms.
- Advisory votes on executive compensation.
- Governed by the company's documents and Delaware law.
AngioDynamics Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped AngioDynamics’s Ownership Landscape?
In the past few years, AngioDynamics has been reshaping its portfolio and strategic focus. A key aspect of this has been the divestiture of several product lines. For example, in February 2024, the company sold its peripherally inserted central catheter (PICC) and related products to Spectrum Vascular. This move, along with the sale of its dialysis product portfolio in June 2023, aims to strengthen the company's financial position and allow it to concentrate on high-growth areas like NanoKnife, Mechanical Thrombectomy, and Auryon businesses. These changes reflect a broader trend in the medical device industry towards streamlining operations and focusing on core competencies.
Further portfolio adjustments include the discontinuation of specific product lines. As of February 2024, AngioDynamics stopped offering products like the Uniblate and StarBurst radiofrequency ablation devices and the Syntrax line of support catheters. These actions are part of a strategic effort to optimize the product mix and improve profitability. The company's financial performance and future outlook are critical factors for investors and stakeholders.
| Metric | Details | Date |
|---|---|---|
| Institutional Ownership | 94.31% | May 2025 |
| GAAP Net Loss | $4.4 million or $0.11 per share | Q3 FY2025 |
| Net Sales Forecast | $282 to $288 million | FY2025 |
| Adjusted EBITDA Forecast | $1.0 to $3.0 million | FY2025 |
Institutional ownership of AngioDynamics remains high, with 94.31% as of May 2025. This indicates a significant level of confidence from institutional investors, even as some have adjusted their positions. For example, UBS GROUP AG increased its holdings. The company's financial results and strategic moves continue to shape the perceptions of AngioDynamics shareholders and the overall AngioDynamics stock performance. For more in-depth information about the business, check out the Revenue Streams & Business Model of AngioDynamics.
AngioDynamics Ownership Trends
Recent strategic initiatives have impacted the AngioDynamics ownership profile. Divestitures and discontinuations of product lines are aimed at focusing on core businesses.
Institutional Investor Activity
Institutional ownership remains high, with adjustments reflecting market conditions. Some investors have increased their holdings, showing confidence in the company's direction.
Financial Performance and Outlook
The company reported a net loss in Q3 FY2025, with expectations for positive Adjusted EBITDA in FY2025. Net sales are projected to be between $282 and $288 million.
Strategic Focus Areas
The company is concentrating on high-growth areas like NanoKnife, Mechanical Thrombectomy, and Auryon. These areas are expected to drive future growth and profitability.
AngioDynamics Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of AngioDynamics Company?
- What is Competitive Landscape of AngioDynamics Company?
- What is Growth Strategy and Future Prospects of AngioDynamics Company?
- How Does AngioDynamics Company Work?
- What is Sales and Marketing Strategy of AngioDynamics Company?
- What is Brief History of AngioDynamics Company?
- What is Customer Demographics and Target Market of AngioDynamics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.